S&P 500   5,035.93 (-0.31%)
DOW   37,824.41 (+0.07%)
QQQ   427.50 (-0.84%)
AAPL   168.62 (-0.45%)
MSFT   412.45 (-0.51%)
META   495.82 (-0.79%)
GOOGL   155.89 (+0.97%)
AMZN   181.45 (-1.02%)
TSLA   157.20 (+0.06%)
NVDA   852.19 (-2.51%)
AMD   156.02 (-4.55%)
NIO   3.95 (+3.67%)
BABA   69.14 (-0.68%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.49 (-3.51%)
GE   155.12 (-1.05%)
CGC   6.60 (-1.49%)
DIS   113.33 (-0.48%)
AMC   2.95 (+8.46%)
PFE   25.44 (-0.97%)
PYPL   63.23 (-0.32%)
XOM   118.49 (-0.17%)
S&P 500   5,035.93 (-0.31%)
DOW   37,824.41 (+0.07%)
QQQ   427.50 (-0.84%)
AAPL   168.62 (-0.45%)
MSFT   412.45 (-0.51%)
META   495.82 (-0.79%)
GOOGL   155.89 (+0.97%)
AMZN   181.45 (-1.02%)
TSLA   157.20 (+0.06%)
NVDA   852.19 (-2.51%)
AMD   156.02 (-4.55%)
NIO   3.95 (+3.67%)
BABA   69.14 (-0.68%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.49 (-3.51%)
GE   155.12 (-1.05%)
CGC   6.60 (-1.49%)
DIS   113.33 (-0.48%)
AMC   2.95 (+8.46%)
PFE   25.44 (-0.97%)
PYPL   63.23 (-0.32%)
XOM   118.49 (-0.17%)
S&P 500   5,035.93 (-0.31%)
DOW   37,824.41 (+0.07%)
QQQ   427.50 (-0.84%)
AAPL   168.62 (-0.45%)
MSFT   412.45 (-0.51%)
META   495.82 (-0.79%)
GOOGL   155.89 (+0.97%)
AMZN   181.45 (-1.02%)
TSLA   157.20 (+0.06%)
NVDA   852.19 (-2.51%)
AMD   156.02 (-4.55%)
NIO   3.95 (+3.67%)
BABA   69.14 (-0.68%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.49 (-3.51%)
GE   155.12 (-1.05%)
CGC   6.60 (-1.49%)
DIS   113.33 (-0.48%)
AMC   2.95 (+8.46%)
PFE   25.44 (-0.97%)
PYPL   63.23 (-0.32%)
XOM   118.49 (-0.17%)
S&P 500   5,035.93 (-0.31%)
DOW   37,824.41 (+0.07%)
QQQ   427.50 (-0.84%)
AAPL   168.62 (-0.45%)
MSFT   412.45 (-0.51%)
META   495.82 (-0.79%)
GOOGL   155.89 (+0.97%)
AMZN   181.45 (-1.02%)
TSLA   157.20 (+0.06%)
NVDA   852.19 (-2.51%)
AMD   156.02 (-4.55%)
NIO   3.95 (+3.67%)
BABA   69.14 (-0.68%)
T   16.13 (+0.25%)
F   12.09 (+0.00%)
MU   117.49 (-3.51%)
GE   155.12 (-1.05%)
CGC   6.60 (-1.49%)
DIS   113.33 (-0.48%)
AMC   2.95 (+8.46%)
PFE   25.44 (-0.97%)
PYPL   63.23 (-0.32%)
XOM   118.49 (-0.17%)
NASDAQ:FULC

Fulcrum Therapeutics (FULC) Stock Price, News & Analysis

$7.32
-0.09 (-1.21%)
(As of 02:22 PM ET)
Today's Range
$7.23
$7.51
50-Day Range
$7.36
$12.00
52-Week Range
$2.42
$13.70
Volume
181,101 shs
Average Volume
652,828 shs
Market Capitalization
$453.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.17

Fulcrum Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
79.9% Upside
$13.17 Price Target
Short Interest
Healthy
3.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of Fulcrum Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$57,240 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.76) to ($1.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.03 out of 5 stars

Medical Sector

353rd out of 914 stocks

Pharmaceutical Preparations Industry

149th out of 416 stocks

FULC stock logo

About Fulcrum Therapeutics Stock (NASDAQ:FULC)

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

FULC Stock Price History

FULC Stock News Headlines

AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
FULC Apr 2024 9.000 put
AI “wealth window” is closing soon!
Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.
FULC Jun 2024 15.000 call
Earnings Preview: Fulcrum Therapeutics
See More Headlines
Receive FULC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fulcrum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/17/2024
Next Earnings (Estimated)
5/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FULC
Fax
N/A
Employees
76
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.17
High Stock Price Target
$17.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+77.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-97,330,000.00
Net Margins
-3,470.05%
Pretax Margin
-3,470.05%

Debt

Sales & Book Value

Annual Sales
$2.81 million
Book Value
$3.80 per share

Miscellaneous

Free Float
60,387,000
Market Cap
$458.98 million
Optionable
Optionable
Beta
2.29
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. Alexander C. Sapir (Age 57)
    CEO, President & Director
  • Dr. Bradley E. Bernstein M.D.
    Ph.D., Founder
  • Dr. Michael R. Green
    Founder
  • Dr. Rudolf Jaenisch M.D.
    Ph.D., Founder
  • Dr. Tsun-Huei Lee M.D. (Age 60)
    Ph.D., Founder
  • Dr. Danny Reinberg
    Founder
  • Mr. Alan A. Musso C.M.A. (Age 62)
    CPA, Chief Financial Officer
  • Mr. Gregory Tourangeau
    Controller & Principal Accounting Officer
  • Dr. Jeffrey W. Jacobs Ph.D. (Age 61)
    Chief Scientific Officer
  • Mr. Curtis G. Oltmans J.D. (Age 61)
    Senior VP, Chief Legal Officer & Corporate Secretary
    Comp: $83.98k

FULC Stock Analysis - Frequently Asked Questions

Should I buy or sell Fulcrum Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulcrum Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FULC shares.
View FULC analyst ratings
or view top-rated stocks.

What is Fulcrum Therapeutics' stock price target for 2024?

6 Wall Street research analysts have issued 1 year target prices for Fulcrum Therapeutics' shares. Their FULC share price targets range from $6.00 to $17.00. On average, they anticipate the company's stock price to reach $13.17 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price.
View analysts price targets for FULC
or view top-rated stocks among Wall Street analysts.

How have FULC shares performed in 2024?

Fulcrum Therapeutics' stock was trading at $6.75 at the start of the year. Since then, FULC shares have increased by 8.4% and is now trading at $7.32.
View the best growth stocks for 2024 here
.

Are investors shorting Fulcrum Therapeutics?

Fulcrum Therapeutics saw a drop in short interest in March. As of March 31st, there was short interest totaling 2,260,000 shares, a drop of 5.4% from the March 15th total of 2,390,000 shares. Based on an average daily volume of 668,800 shares, the short-interest ratio is currently 3.4 days.
View Fulcrum Therapeutics' Short Interest
.

When is Fulcrum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our FULC earnings forecast
.

How were Fulcrum Therapeutics' earnings last quarter?

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) posted its quarterly earnings data on Tuesday, February, 27th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.04. The firm earned $0.87 million during the quarter, compared to analyst estimates of $0.65 million. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative trailing twelve-month return on equity of 36.65%.

What ETFs hold Fulcrum Therapeutics' stock?

ETFs with the largest weight of Fulcrum Therapeutics (NASDAQ:FULC) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Simplify Health Care ETF (PINK) and SPDR S&P Pharmaceuticals ETF (XPH).Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).

What other stocks do shareholders of Fulcrum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulcrum Therapeutics investors own include VIVUS (VVUS), Provention Bio (PRVB), Entasis Therapeutics (ETTX), Kaleido Biosciences (KLDO), VBI Vaccines (VBIV), Xeris Biopharma (XERS), CymaBay Therapeutics (CBAY), Evelo Biosciences (EVLO) and Akero Therapeutics (AKRO).

When did Fulcrum Therapeutics IPO?

Fulcrum Therapeutics (FULC) raised $76 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 4,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and SVB Leerink acted as the underwriters for the IPO.

Who are Fulcrum Therapeutics' major shareholders?

Fulcrum Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Mass General Brigham Inc (0.33%). Insiders that own company stock include Christopher Morabito, Curtis Gale Oltmans, Greg Tourangeau, James A Geraghty, Peter G Thomson, Ra Capital Management, LP, Robert J Gould and Robert J Gould.
View institutional ownership trends
.

How do I buy shares of Fulcrum Therapeutics?

Shares of FULC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FULC) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners